Geneva, March 23 -- International Clinical Trials Registry received information related to the study (ChiCTR2600120129) titled 'Deuremidevir Hydrobromide Tablets (VV116) Clinical Application Demonstration Project for the Treatment of SARS-CoV-2 Infection' on March 10.
Study Type: Observational study
Study Design:
Cohort study
Primary Sponsor: Shanghai Public Health Clinical Center
Condition:
Novel coronavirus infection (COVID-19)
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-03-15
Target Sample Size: COVID-19 patients treated with deuterated remidevir hydrobromide tablets:3347;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=301926
Published b...